Name | 2-chloro-1-N,4-N-bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]benzene-1,4-dicarboxamide |
---|---|
Synonyms |
Glycopeptide,3b
Wander HR 2198 |
Description | NSC-60339, an efflux pump inhibitor and a substrate of AcrAB-TolC, is a polybasic terephthalic acid derivative studied as a potential cancer chemotherapeutic agent[1][2]. |
---|---|
Related Catalog | |
In Vitro | NSC 60339 has been correlated with the sensitivity, resistance, or cross-resistance of 7 tumor lines to phthalanilide treatment in vivo. The sensitive tumors (L1210, L1210/MTX, L1210/ara-C, and P815) rapidly takes up the drug and retained it primarily as lipid-bound drug for the 24-hr experimental period. The resistant tumor, L1210/NSC 60339, and 2 cross-resistant tumors, P388/VCR and P815/VLB, took up as much drug as the sensitive tumors did by 0.5 hr, but there was an efflux of lipid-bound drug from these resistant tumors by 24 hr[3]. |
References |
Molecular Formula | C26H23ClN6O2 |
---|---|
Molecular Weight | 486.95300 |
Exact Mass | 486.15700 |
PSA | 106.98000 |
LogP | 3.21900 |
Storage condition | -20°C |